One to 2 ml of morning fasting blood samples were collected, serum prepared, and stored at −70°C. Carboxy-terminal telopeptide of type 1 collagen (CTX, β-CrossLaps, Cobas, Roche, Rotkreuz, Switzerland) and procollagen type 1 amino-terminal propeptide (P1NP, Cobas, Roche, Rotkreuz, Switzerland) were quantified as a reference for bone metabolism/formation [20 ]. Coefficient of variation (CV) analysis was performed (3% for P1NP and 6% for CTX, lab certified in accordance with ISO 15189:201).
β crosslaps
Manufactured by Roche
Sourced in Switzerland
β-CrossLaps is a laboratory assay used to measure the levels of C-terminal telopeptide of type I collagen (CTX-I) in blood or urine samples. CTX-I is a biochemical marker that reflects the rate of bone resorption. This assay provides quantitative information about bone turnover.
Automatically generated - may contain errors
Lab products found in correlation
6 protocols using β crosslaps
1
Bone Metabolism Markers Quantification
2
Serum Biomarkers of Bone Metabolism
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The βCTX (β-CrossLaps; cat#: 11972308 122) was measured from serum at the Mount Sinai Hospital Core Laboratory (Toronto, Ontario) using a Roche Cobas e602 automated analyzer. Lower and upper detection limits were 0.010–6.00 ng/ml (quality control standard CV: 4.8%). Serum concentrations of sclerostin, OC, OPG and RANKL were measured in duplicate with intra-assay and inter-assay coefficients of variation (CVs) measured in house. Sclerostin was measured using an enzyme-linked immunosorbent assay (ELISA; cat# DSST00; R&D, Minneapolis, MN). OC and OPG were measured using a microbead multiplex kit (cat# HBNMAG-51K-08, EMD Millipore, Darmstadt, Germany) and RANKL was measured using a microbead single-plex kit (cat# HRNKLMAG-51K-01, EMD Millipore, Darmstadt, German). The average intra-assay CVs for sclerostin, OC, OPG, and RANKL were 5.4, 5.6, 4.8, and 6.1%, respectively. The average inter-assay CVs for sclerostin, OC, OPG, and RANKL were 5.7, 6.4, 5.1, and 4.1%, respectively.
3
Peri-Operative Bone Turnover Assessment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All blood samples were acquired fasting in the morning 7–14 days before surgery, 1–3 days post-surgery, and after 3, 6, 12, and 24 months. Carboxy-terminal telopeptide of type 1 collagen (CTX, β-CrossLaps, Cobas, Roche, Basel, Switzerland) was measured as a bone resorption marker and procollagen type 1 amino-terminal propeptide (P1NP, Cobas, Roche) as a bone formation marker.
Our laboratory is certified according to the international standard ISO 15189:201. The CV was 3% for P1NP and 6% for β-CrossLaps.
Our laboratory is certified according to the international standard ISO 15189:201. The CV was 3% for P1NP and 6% for β-CrossLaps.
4
Comprehensive Biochemical and Bone Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All biochemical markers were measured at the same time point using the same reagent kits by the same technician, following both the manufacturer-provided operating processes and specialized assay laboratory quality control procedures. Plasma glucose was determined using the glucose oxidase method and an autoanalyzer (Beckman Coulter AU5800; Tokyo, Japan). Serum levels of alanine transferase (ALT), aspartate transferase (AST), alkaline phosphatase, creatinine, uric acid, urea nitrogen, calcium, phosphorus, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were also examined (Beckman Coulter AU5800; Tokyo, Japan).
Serum concentrations of insulin, CTX, and P1NP were measured using a computer-controlled automatic analyzer (Roche cobas e 601; Mannheim, Germany) for chemiluminescence workstation with insulin, β-Crosslaps, and total P1NP Elecsys reagent kits supplied by Roche Diagnostics (Mannheim, Germany). The intra- and inter-assay coefficients of variation (CV) were 2.3% and 4.1% for insulin, 2.4% and 3.6% for CTX, 2.1% and 3.4% for P1NP, respectively.
Bone mineral densities (BMDs) of the lumbar spine and femur were determined by dual-energy X-ray absorptiometry (Hologic, Bedford, MA, USA).
Serum concentrations of insulin, CTX, and P1NP were measured using a computer-controlled automatic analyzer (Roche cobas e 601; Mannheim, Germany) for chemiluminescence workstation with insulin, β-Crosslaps, and total P1NP Elecsys reagent kits supplied by Roche Diagnostics (Mannheim, Germany). The intra- and inter-assay coefficients of variation (CV) were 2.3% and 4.1% for insulin, 2.4% and 3.6% for CTX, 2.1% and 3.4% for P1NP, respectively.
Bone mineral densities (BMDs) of the lumbar spine and femur were determined by dual-energy X-ray absorptiometry (Hologic, Bedford, MA, USA).
5
Serum Biomarkers for Osteoarthritis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Retrospective analysis of serum concentrations of C1M, C2M, C3M, and CRPM from patients from MOBILITY part A were measured at Synarc (BioClinica Laboratory, Lyon, France) using a validated proprietary enzyme-linked immunosorbent assay (ELISA) by Nordic Bioscience (Herlev, Denmark). The intra-assay and inter-assay variation (coefficients of variation (CVs)) were <13.8 % for C1M, <19.8 % for C2M, <16.4 % for C3M, and <14.2 % for CRPM. Serum concentrations of C1M, C2M, C3M, MMP-3, CTX-1, and OC from patients from MOBILITY part B were measured at Nordic Bioscience using a validated ELISA (Nordic Bioscience; all CVs <15 %). Serum MMP-3 (Quantikine total MMP-3 (R&D Systems, Minneapolis, MN, USA); CV <10 %) and serum CTX-1 (CV <3.4 %) were measured using the β-CrossLaps (Roche, Basel, Switzerland) assay. Osteocalcin was measured using the validated N-MID-OC kit (Roche; CV <4.6 %). Serum concentrations of sRANKL (human sRANKL ELISA (BioVendor, Brno, Czech Republic)) and OPG (human OPG ELISA (BioVendor)) were measured using validated assays at Pacific Biomarkers (Seattle, WA, USA).
6
Serum Bone Turnover Markers Quantification
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The serum levels of bone turnover markers, osteocalcin (OC) and β-CrossLaps (β-CTx), were determined by using the N-MID Osteocalcin kit (Cobas-Roche, Switzerland) and β-CrossLaps kit (Cobas-Roche, Switzerland), respectively. OC and β-CTx were analysed with the electrochemiluminescence immunoassay “ECLIA” and immunoassay analyser Elecsys 2010 (Hitachi High-Technologies Corporation, Tokyo, Japan) according to the manufacturers’ instructions.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!